This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Aduro Biotech stock

Own Aduro Biotech stock in just a few minutes.

Posted

Fact checked

Aduro Biotech, Inc is a biotechnology business based in the US. Aduro Biotech shares (ADRO) are listed on the NASDAQ and all prices are listed in US Dollars. Aduro Biotech employs 69 staff and has a trailing 12-month revenue of around USD$28 million.

How to buy shares in Aduro Biotech

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Aduro Biotech. Find the stock by name or ticker symbol: ADRO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aduro Biotech reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Aduro Biotech, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Aduro Biotech. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Aduro Biotech share price

Use our graph to track the performance of ADRO stocks over time.

Aduro Biotech shares at a glance

Information last updated 2020-11-22.
52-week range USD$4.9 - USD$20.2
50-day moving average USD$3.71
200-day moving average USD$2.9131
Wall St. target price USD$18.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.15

Buy Aduro Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aduro Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Aduro Biotech under- or over-valued?

Valuing Aduro Biotech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aduro Biotech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Aduro Biotech's PEG ratio

Aduro Biotech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.06. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Aduro Biotech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Aduro Biotech financials

Revenue TTM USD$28 million
Gross profit TTM USD$-48,610,000
Return on assets TTM -13.9%
Return on equity TTM -87.44%
Profit margin -230.92%
Book value $2.875
Market capitalisation USD$236.6 million

TTM: trailing 12 months

Shorting Aduro Biotech shares

There are currently 3.2 million Aduro Biotech shares held short by investors – that's known as Aduro Biotech's "short interest". This figure is 2.7% down from 3.3 million last month.

There are a few different ways that this level of interest in shorting Aduro Biotech shares can be evaluated.

Aduro Biotech's "short interest ratio" (SIR)

Aduro Biotech's "short interest ratio" (SIR) is the quantity of Aduro Biotech shares currently shorted divided by the average quantity of Aduro Biotech shares traded daily (recently around 688870.17167382). Aduro Biotech's SIR currently stands at 4.66. In other words for every 100,000 Aduro Biotech shares traded daily on the market, roughly 4660 shares are currently held short.

However Aduro Biotech's short interest can also be evaluated against the total number of Aduro Biotech shares, or, against the total number of tradable Aduro Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aduro Biotech's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aduro Biotech shares in existence, roughly 40 shares are currently held short) or 0.0486% of the tradable shares (for every 100,000 tradable Aduro Biotech shares, roughly 49 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aduro Biotech.

Find out more about how you can short Aduro Biotech stock.

Aduro Biotech share dividends

We're not expecting Aduro Biotech to pay a dividend over the next 12 months.

Have Aduro Biotech's shares ever split?

Aduro Biotech's shares were split on a 1:5 basis on 2 October 2020. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aduro Biotech shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Aduro Biotech shares which in turn could have impacted Aduro Biotech's share price.

Aduro Biotech share price volatility

Over the last 12 months, Aduro Biotech's shares have ranged in value from as little as $4.9 up to $20.2. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aduro Biotech's is 0.3861. This would suggest that Aduro Biotech's shares are less volatile than average (for this exchange).

Aduro Biotech overview

Aduro Biotech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase II clinical trial in combination with pembrolizumab, an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and natural killer cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; and license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro Biotech, Inc. in June 2008. Aduro Biotech, Inc. was founded in 2000 and is headquartered in Berkeley, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site